Protocol Ledger

NCT03587740 · Phase II · ACTIVE NOT RECRUITING

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

Interventional Phase II clinical trial protocol NCT03587740 sponsored by Dana-Farber Cancer Institute in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-08-22 Enrollment: 111 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03587740
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)111 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03587740
Protocol FieldVerified Registry Value
NCT IdentifierNCT03587740
Consolidated Lead SponsorDana-Farber Cancer Institute
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment111 participants (ACTUAL)
Registered Start Date2018-08-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Dana-Farber Cancer Institute across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI